G1 reaffirmed its full year 2024 financial guidance. The company expects to generate between $60 million and $70 million in COSELA net revenue in 2024. G1’s product revenue guidance is based on expectations for continued acceleration of sales performance of COSELA in the U.S. Additionally, the company believes that its current cash runway is sufficient to fund its operations into the third quarter of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GTHX:
- G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
- G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
- G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
- G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)